Conference begins
  • No dates present
  • Industry-Supported Symposia

    Wednesday July 6

    Sanofi Genzyme

    12:00-13:30

    Room: Grand Ballroom Centre

    Luncheon Symposium supported by Sanofi Genzyme

    Pompe Medical Expert Symposium

    Chair & Moderator: Dr. Vera Bril

    • Introduction of Late Onset Pompe Disease: Dr. Mark Tarnopolsky, McMaster University, Hamilton, ON
    • Diagnostic Strategies of LGMW Including Next Generation Sequencing: Dr. Matthew Harms, Columbia University, New York, NY

    See here for more details.

    17:15-18:15

    Room: Osgoode Ballroom West

    Evening Symposium supported by Akashi Therapeutics

    Multi-pathway Approach to DMD Treatment

    Chair: Diana Escolar

    • Antifibrotics: HT-100 For The Treatment Of DMD: Diana Escolar, MD, Chief Medical Officer, Akashi Therapeutics, Inc.
    • Modulating Calcium Homeostasis: AT-300 Effects In MDX Model Of DMD: Ernest D. Bush, Ph.D, Chief Scientific Officer, Akashi Therapeutics, Inc.
    • A Novel Approach To Building Muscle In DMD: DT-200, Selective Androgen Receptor Modulator: Diana Escolar, MD, Chief Medical Officer, Akashi Therapeutics, Inc.

    See here for more details.

     

     

    Thursday July 7

    7:00-8:00

    Room: Grand Ballroom West

    Breakfast Symposium supported by Terumo BCT

    The immunomodulatory role of plasma exchange in PNS & Neuromuscular diseases: A Presentation & clinical debate

    • Plasma exchange immune-modulation & mechanism of action: Prof. Hans-Peter Hartung, Heinrich-Heine-Universität, Düsseldorf, Germany
    • Clinical debate on the place of plasma exchange in PNS & neuromuscular diseases (acute & chronic), addressing current evidence & unmet medical needs:
      • Prof. Jean-Marc Leger, MD, FAAN, University Hospital Pitié-Salpêtrière, Paris, France
      • Prof. Mazen Dimachkie, University of Kansas Medical Center, Kansas City, KS

    See here for more details.

    7:00-8:00

    Room: Osgoode Ballroom East

    Breakfast Symposium supported by CSL Behring

    Updates in Myasthenia Gravis

    Chair: Dr. Vera Bril

    • Novel Clinical Assessment Methods in Myasthenia Gravis: Dr. Carolina Barnett, University Health Network and University of Toronto, ON
    • Recent Updates in the Treatment of Myasthenia Gravis: Dr. Zaeem A. Siddiqi, University of Alberta Hospital, Edmonton, AB

    See here for more details and to RSVP.

    7:00-8:00

    Room: Osgoode Ballroom West

    Breakfast Symposium supported by Idera

    Advances in Myositis: Immune Mechanisms of Disease, Current Clinical Practice and Future Directions

    Moderator: Kirsten Gruis, MD, Senior Medical Director, Rare Diseases, Idera Pharmaceuticals

    • Toll-Like Receptors and Innate Immune Mechanisms of Muscle Disease: Kanneboyina Nagaraju, DVM, PhD, George Washington University School of Medicine and Health Sciences; Children’s National Medical Center, Washington, DC
    • Current Understanding of Standards of Care and Management of Inflammatory Myopathies: Anthony A. Amato, MD, Brigham and Women’s Hospital; Harvard Medical School, Boston, MA

    See here for more details and to RSVP.

    Alnylam 17:15-18:15

    Room: Osgoode Ballroom West

    Evening Symposium supported by Alnylam

    The Patient Journey: From symptom onset to new treatment horizons in hereditary ATTR amyloidosis with polyneuropathy (hATTR-PN)

    • Patient journey and unmet medical needs in hATTR-PN
    • Natural history, treatment options and clinical assessment tools in hATTR-PN
    • Development of RNAi therapeutics as a potential treatment option for patients wtih hATTR-PN

    Presenters:

    • Michelle Mezei, MD (Canada)
    • P James Dyck, MD (USA)
    • Alejandra Gonzalez Duarte, MD (Mexico)

    See here for more details.

    Friday July 8

    12:00-13:30

    Room: Osgoode Ballroom West

    Luncheon Symposium supported by PTC Therapeutics

    The Evolving Management of Duchenne Muscular Dystrophy

    Chair: Jean K. Mah

    • The Evolving Understanding of Clinical End Points and Meaningfulness: Jean K. Mah, MD, MSc, FRCPC, University of Calgary; Alberta Children's Hospital, Calgary, AB
    • The Future of Duchenne Treatments: Perry Shieh, MD, PhD, David Geffen School of Medicine at UCLA, Los Angeles, CA

    See here for more details and to RSVP.

     

     

    Saturday July 9

    7:00-8:00

    Room: Grand Ballroom West

    Breakfast Symposium supported by Alexion

    Recognizing the Patient with Refractory Myasthenia Gravis: An Interactive Workshop

    Moderator: Karen Gondek

    • Refractory MG
    • Assessment tools and MG‐ADL

    Presenters:

    • Srikanth Muppidi, MD, Stanford School of Medicine, Stanford, CA
    • Richard J. Nowak, MD, MS, Yale School of Medicine, New Haven, CT
    • Nicholas J. Silvestri, MD, University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY
    • Gil I. Wolfe, MD, FAAN, University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY

    See here for more details.

    Grifols7:00-8:00

    Room: Osgoode Ballroom West

    Breakfast Symposium supported by Grifols

    Measuring response and need to continue treatment in CIDP: Moving from ICE trial outcome measures to future clinical biomarker

    Chair: Hans Katzberg, MD

    • Residual conduction block after IVIG as a predictor of relapse in CIDP: Norman Latov, MD, Weill Cornell Medical Center, New York, NY
    • Real-time ultrasound monitoring of same lesions as a biomarker of therapeutic efficacy in CIDP: Francis Walker, MD, Wake Forest University, Winston-Salem, NC

    See here for more details.

    12:00-13:30

    Room: Grand Ballroom West

    Luncheon Symposium supported by Santhera

    Advances in pulmonary care in DMD

    Chair: Oscar H Mayer

    • Overview of respiratory function measures: Oscar H Mayer, The Children's Hospital of Philadelphia, PA
    • The natural history of respiratory functional decline in DMD: Erik Henricson, Physical Medicine and Rehabilitation Neuromuscular Research Center, Sacramento, CA
    • Current standards of care and future perspectives: Oscar H Mayer
    • Treatment strategies to slow decline in respiratory function in DMD - Report of the DELOS Phase III trial: Gunnar Buyse, University of Leuven, Belgium

    See here for more details.

    Follow ICNMD 2016:

    Twitter

    CONFERENCE NEWSLETTER

    Switch To Full Site

    Welcome to ICNMD!

    You’ve found the site of one of our past conferences.

    To view our most recent conference information visit www.ICNMD.org

    To continue viewing this website, please close this box.